The subscription period for Chordate Medical’s ongoing rights issue runs until Monday, February 17, 2025. However, some banks may close the subscription earlier.
Subscription can be made with Bank-ID here, or through your bank or broker. In the rights issue, a unit consisting of one ordinary share and one preference share, intended to be listed on Nasdaq First North Growth Market, is being issued. The subscription price for one unit is 12 SEK.
“The primary goal of this capital raise is to continue driving the ongoing exit process to a desired outcome, and in addition, to finance the activities and measures we believe are necessary to achieve that,” says Anders Weilandt, CEO of Chordate.
CEO Anders Weilandt is interviewed about the rights issue here (In Swedish)
In the event of full subscription in the rights issue, the Company will receive net cash of approximately SEK 20.6 M (after issue costs). The net proceeds are intended to be used for the following purposes, listed in order of priority:
- General company purposes (approx. 50 percent)
- Completion of clinical studies (approx. 10 percent)
- Continued processing of focus markets (approx. 30 percent)
- Investments in production capacity (approx. 10 percent)
Information memorandum and more details about the rights issue (In Swedish)
